Elsevier

Neurobiology of Disease

Volume 8, Issue 2, April 2001, Pages 343-350
Neurobiology of Disease

Regular Article
Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys

https://doi.org/10.1006/nbdi.2000.0375Get rights and content

Abstract

GABA and enkephalin-utilizing efferents from the striatum to the external segment of the pallidal complex (GPe) are thought to be overactive in Parkinson's disease (PD). This overactivity is generally held to play a major role in the genesis of parkinsonian symptoms, which are thought to appear when dopaminergic neuronal death exceeds a critical threshold. Little is known, however, regarding the activity of this pathway during disease progression and more particularly, prior to the emergence of parkinsonian symptoms. In order to test the hypothesis that an upregulation of striatal preproenkephalin-A (PPE-A) mRNA levels occurs before the appearance of parkinsonian motor disabilities, the present study assessed PPE-A mRNA expression and striatal dopamine (DA) content following a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration protocol in monkeys that produces a progressive parkinsonian state. Groups ranged from normal to full parkinsonian through asymptomatic lesioned monkeys. The key finding of this study is that PPE-A expression is already upregulated in asymptomatic-lesioned monkeys showing a marked DA depletion (56%). Importantly, this up-regulation is restricted to motor regions of the basal ganglia circuitry. The increased PPE-A mRNA expression observed in asymptomatic, but DA-depleted animals, supports our initial hypothesis of such an upregulation occurring before the appearance of parkinsonian motor disabilities. Furthermore, when considered with recent electrophysiological and histochemical data, these findings question the functional significance of upregulated enkephalin transmission in the indirect striatopallidal pathway.

References (40)

  • I.J. Mitchell et al.

    Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

    Neuroscience

    (1989)
  • A.P. Nisbet et al.

    Preproenkephalin and preprotatachykinin messenger RNA expression in normal basal ganglia and in Parkinson's disease

    Neuroscience

    (1995)
  • L.K. Nisenbaum et al.

    Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion

    Neuroscience

    (1994)
  • A. Parent et al.

    Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop

    Brain Res. Rev.

    (1995)
  • D.J.S. Sirinathsinghji et al.

    Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: Dependence on sodium but not calcium ions

    Brain Res.

    (1988)
  • Y. Agid

    Parkinson's disease: Pathophysiology

    Lancet

    (1991)
  • M.C. Asselin et al.

    Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys

    Neuroreport

    (1994)
  • J.H. Baik et al.

    Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors

    Nature

    (1995)
  • E. Bezard et al.

    Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms

    Eur. J. Neurosci.

    (1999)
  • Cited by (55)

    • Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

      2015, Progress in Neurobiology
      Citation Excerpt :

      Overall, these studies bring evidence for a hyperactivity of glutamatergic neurons in response to chronic L-dopa that may operate in a region-dependent manner. Accordingly, L-dopa is expected to change GABA release in the basal ganglia (Bezard et al., 2001d; Cenci, 2007b). In dyskinetic mice, L-dopa enhances GABA release in the SNr and GP (Bido et al., 2011).

    • Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections

      2014, Neuron
      Citation Excerpt :

      One animal was kept untreated as control. The other animal received daily MPTP (0.2 mg/kg, i.v.) according to previously published protocol (Bezard et al., 1997, 2001a, 2001b). Following stabilization of the MPTP-induced syndrome, animal behavior was assessed as previously published (Ahmed et al., 2010; Fasano et al., 2010; Fernagut et al., 2010; Muñoz et al., 2008; Porras et al., 2012).

    View all citing articles on Scopus
    1

    To whom correspondence and reprint requests should be addressed at his present address: Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Université Victor Segalen, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France. Fax: 33 556 901 421. E-mail: [email protected].

    View full text